Claudin 18.2

Ongoing clinical trials and approved products targeting Claudin 18.2, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

Theranostic pair: this target is explored in both imaging and therapy.

1ongoing therapy trials
2ongoing imaging trials
0approved products

Target note

Full name
Claudin 18, isoform 2
Nature
Tight junction protein, hidden in healthy epithelium and exposed at the surface in tumors.
Normal expression
Differentiated cells of the gastric mucosa.
Disease expression
Gastric, gastroesophageal junction and pancreatic adenocarcinomas.
Value
A target validated by zolbetuximab in gastric cancer.
Approaches
IR199 vector labeled with ¹³¹I, paired with ⁶⁸Ga for imaging.
Indications explored
Claudin 18.2-positive gastric and pancreatic cancers (phase 1).
Points of caution
Exposure of the healthy gastric mucosa.

Ongoing therapy trials · 1Open in the radar →

TrialPhaseStatusSponsorCountries
[131I]IR199NCT07707531 · Pancreas (adenocarcinoma)Phase 1RecruitingHuashan Hospital1

Ongoing imaging trials · 2Open in the radar →

TrialPhaseStatusSponsorCountries
Claudin 18.2 tracersNCT06646783 · Pancreas (adenocarcinoma)Phase 1Not yet recruitingSmartNuclide Biopharma1
Claudin 18.2 tracersNCT07597772 · Pancreas (adenocarcinoma)Phase 1RecruitingSmartNuclide Biopharma1

Cite this page

Claudin 18.2. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/claudin-18-2/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.